Classification of New Biomarkers of Dilated Cardiomyopathy Based on Pathogenesis—An Update

Muhammad Nabeel Dookhun¹², Yali Sun¹, Huayiyang Zou¹, Xiaoqian Cao¹, Xinzheng Lu¹²*

¹Department of Cardiology, The First Affiliated Hospital, Nanjing Medical University, Jiangsu, China
²Department of Cardiology, Sir Run Run Hospital Nanjing Medical University, Jiangsu, China
Email: *xzl@njmu.edu.cn

Abstract

Dilated Cardiomyopathy (DCM) is a complex heart disease affecting the heart musculature and vasculature, involving one or several underlying pathophysiological mechanisms. Identifying potential biomarkers for dilated cardiomyopathy is a challenge owing to various etiologies involved. Studying the biomarkers involved in DCM will ultimately give a better insight about which pathophysiological pathways are involved in the onset of the disease. Owing to its multifactorial etiologies, response to treatment is usually poor. If we can find the exact underlying causes, a better treatment approach could be implemented. One way to obtain better insight of DCM is to study the biomarkers released. Through biomarkers, we can know which underlying mechanisms are involved. Biomarkers can provide us with clinical information such as diagnostic, prognostic, risk stratification as well as response to treatment. Underlying mechanisms such as inflammation, stress/strain, myocyte injury, matrix remodelling, oxidative stress, neurohormones involvement, among others, can contribute to the onset of DCM. Different mechanisms will yield different biomarkers. So it would be wise to classify those biomarkers involving in DCM based on their respective pathogenesis. Moreover, most importantly is to be able to make use of the information that biomarker pertains. However, specificity of those biomarkers poses a problem. One way of making these biomarkers clinically useful is to make use of a biomarker modelling score system.

Keywords

Dilated Cardiomyopathy, Biomarkers, Biomarkers Model, Biomarker Score, DCM Biomarkers, New Biomarkers

DOI: 10.4236/health.2018.103024   Mar. 19, 2018   300
1. Introduction

DCM is a common cause of heart failure, which can affect all population groups. DCM can be inherited or acquired which leads to structural and functional changes that eventually result in cardiac dysfunction and hence heart failure. Male is more affected than female with an incidence ratio of 3:1 [1] and while the exact reason still remains unclear, it can be explained by SHBG, which alters the cardiac structure and function [2]. Macroscopically, DCM is characterised by increased ventricular sizes and impaired systolic functions [3] while microscopically it is characterized by a histological triad of myocyte hypertrophy, myocyte degradation, and interstitial fibrosis [4].

DCM can be classified either as primary/idiopathic if of unknown aetiology. Gene mutations can cause familial DCM [5] [6] [7] and among the idiopathic cases, one third can be accounted to familial DCM [8] [9]. DCM can also be attributed to secondary causes including acquired conditions and diseases such as hypertension, alcohol intake, viral infections, drugs among others. The clinical consequences of DCM in paediatric populations are associated with low survival rate and poor outcome [10]. After the emergence of DCM symptoms, 50% of DCM patients die within five years [11] [12]. In order to implement better therapeutic strategies, we need to first understand the diverse pathological mechanisms underlying DCM. One way to get a better insight about the DCM is to study the biomarkers involved in DCM (Figure 1).

2. Biomarkers of Inflammation

Inflammatory biomarkers are involved in the pathophysiologic mechanism of
heart failure and monitoring these biomarkers can provide better insight in terms of diagnosis, prognostics and outcomes of treatment [13] [14].

1) CRP (C-Reactive Protein) & hs-CRP (Prognostic Biomarker)

CRP is an important biomarker of inflammation as well as a causative factor of endothelial dysfunction [15] [16]. Irrespective of the cause, serum level of hs-CRP is increased in CHF patients [17] [18] [19]. Based on studies, elevated hs-CRP level has been found to be a reliable prognostic biomarker of chronic heart failure [20] [21] and that CRP level can independently predict outcome of disease in DCM patients [17] [22]. Endothelial dysfunction, which can be caused by CRP, is also involved in the pathogenesis and prognosis of CHF [23]. Therefore CRP can be used as a prognostic indicator of CHF patients with DCM. The combination of hs-CRP and BNP provide a better prognostic insight in term of mortality [24]. Xiaopin Li et al. confirmed that elevated hs-CRP and NT pro-BNP have higher rate of mortality in CHF patients with DCM [25].

2) Neutrophil/Lymphocyte ratio (NLR) (Prognostic Biomarker)

Following inflammation in heart failure, leukocytes have an important implication in its pathogenesis, mainly reflecting the progression and worsening of heart failure [26] [27]. Increased mortality in HF patients is reflected by neutrophilia and lymphocytopenia [28] [29]. NLR has been shown to be an eligible biomarker for several cardiovascular diseases [30]. Moreover, NLR correlates positively with heart parameters, including LVEF and is related to severity of DCM [31]. Cardiac remodelling in DCM causes ventricular systolic dysfunction of which LVEF can be a good indicator [32]. This suggests that evaluation of chronic heart failure in DCM patients using NLR as biomarkers is a non-invasive and cheap possibility.

3) Chemerin (prognostic)

Chemerin, an adipokine secreted by adipose tissue in response to inflammatory stimulations such as TNF-alpha and IL-1B [33] [34], has been recently found to be significantly elevated in DCM patients [35]. As discussed above, LVEF is a reliable indicator of heart function in DCM patients. Previous studies have shown that positive relationship between LVEF and chemerin level does exist [35] [36]. More studies are needed to investigate whether a high level of chemerin in DCM patients is associated with recurrent adverse cardiac events.

4) Galectin-3 (Gal-3)

Gal-3, an inflammatory component, also acts a regulator of cardiac fibrosis by stimulating fibroblast proliferation that result in excessive collagen in hypertrophied heart and thus causing cardiac dysfunction [37] [38]. Cardiac fibrosis is common in DCM and its presence suggests a more serious disease condition and worse prognosis mainly due to accelerated heart dysfunction [39] [40] [41]. Vergaro et al. first reported the relationship between serum Gal-3 level and myocardial fibrosis in DCM patients [42].

3. Biomarkers of Myocyte Stress/Strain

1) BNP & NT-proBNP
BNP & NT-proBNP are typical traditional biomarkers of heart failure used for diagnosis, screening and prognosis purposes [43]. Ventricular stresses such as pressure overload and volume expansion are responsible for the secretion of BNP [25] [44]. Increased level of BNP or NT-proBNP was found to be a strong predictor of mortality and adverse cardiac events in HF and DCM [45] [46]. Owing to a longer half-life, NT-proBNP is of better clinical use than BNP [25] [47].

2) ST2/Interleukin-33

ST2, an interleukin IL-1 receptor, is known to be a biomarker of heart failure by predicting the extent of cardiac remodelling and fibrosis [48] [49]. ST2 is expressed in cardiac cells and up-regulated in response to mechanical strain and IL-1β [50]. It is considered as a superior biomarker because unlike other biomarkers such as BNP, NT-proBNP, troponin among others, is independent of age, BMI, sex, renal function or heart failure history [49]. Even being a good prognostic biomarker of heart failure no actual current report of the role of ST2 in DCM patients is available.

4. Biomarkers of Myocyte Injury

1) High-Sensitivity Cardiac Troponin T (hs-cTnT)

Studies have highlighted the eligibility of troponins as prognostic markers in DCM patients [51] [52]. hs-cTnT, a new generation of troponin biomarker, is now being widely used owing to its potential of detecting cardiac injury to the minimal extent. An increased level of serum hs-cTnT reflects ongoing myocardial damage [51]. Yuichi Baba et al. defined a cut-off value of 0.014 ng/mL, whereby DCM patients with value less than the cut-off value tends to have reverse remodelling and those greater than the cut-off value experienced no reverse remodelling [53]. This implies hs-cTnT provides a better risk stratification in DCM patients.

2) Heart-type fatty acid binding protein (H-FABP)

H-FABP, an important fatty acid carrier protein of low molecular weight, is present abundantly in the cytoplasm [54]. Thus following cellular damage, H-FABP is quickly released into circulation and this can be attributed to ongoing myocardial damage associated to DCM [55]. The clinical use of H-FABP and BNP combination provide better prognostic value. Elevated level of both markers suggests a worse prognosis in DCM patients [54].

3) Myosin Binding Protein-C (MyBP-C)

MyBP-C, a structural protein, is crucial for cardiac regulatory functions and possesses a N-terminus with multiple phosphorylation sites. Phosphorylation of these PKA sites is of crucial importance reduced phosphorylation of these PKA sites has been shown in DCM patients [56]. Moreover, MyBP-C can elicit an autoimmune response, which results in production of autoantibodies. Following post-MI, proteolysis of COC1 fragment of My-BP-C elicits autoantibodies production. These autoantibodies act on other contractile cardiac protein resulting
in autoimmune myocarditis, which ultimately progress, to DCM and HF [57]. Kasahara et al. first reported the presence of MyBP-C reactive autoantibodies in DCM patients [58]. Onset of autoimmune myocarditis and DCM has also been related to presence of cardiac protein autoantibodies [59].

5. Biomarkers of Extracellular-Matrix Remodeling

1) Matrix metalloproteinases (MMP) & Tissue Inhibitors of Metalloproteinases (TIMP)

As discussed above, cardiac fibrosis occurs in DCM and remodelling of ventricles progress to HF [45]. Proliferation of fibroblast and deposition of collagen in extracellular matrix is responsible for scar tissue formation. MMPs, whose activities are markedly increased in the progression to HF, and TIMPs usually, exist in balance [60]. Inflammatory situations can disrupt the balance between MMPs and TIMPs hence causing collagen deposition and ventricular remodelling that eventually progresses to DCM and HF.

6. Biomarkers of Oxidative Stress

1) Myeloperoxidase (MPO)

MPO is a leukocyte heme peroxidase that has direct effect on ventricular remodelling following post infarction and is associated with neutrophil activation and inflammation [61] [62]. It has been shown that those with low LVEF < 35% on echocardiography, MPO was related to poor right ventricular dysfunction and was a good predictor of future adverse clinical outcomes [63]. MPO can not only used to predict risk in heart failure patients but also used to monitor anti-inflammatory effect in heart failure.

7. Neurohormones Biomarkers

1) Endothelin-1 (ET-1)

ET-1, a 21 amino acid residue with both vasoactive and mitogenic effects [64], has been reported to increase in plasma of DCM patients [65] and endothelin-1 mRNA levels to be unregulated in the heart [66]. Moreover, interestingly two polymorphisms of the endothelin type A receptor gene (EDNRA), G231A and CA363T, are differently related to the risk and mortality in idiopathic DCM patients [67] [68]. Studies have even documented that activation of endothelin is associated with a poor prognosis in DCM patients [69] [70].

8. Others/Unclassified Biomarkers

1) Epithelial Progenitor Cell-EPC

DCM is sometimes referred as a two hit diseases [71] for involving structural cardiac alterations and defective vascularization simultaneously [72]. EPCs are bone marrow derived cells, which are increased in response to vascular injuries through mediators such as VEGF-A and SDF-1 [73]. Studies have reported elevated EPCs level in DCM patients and have further been confirmed by Theiss et
al. who showed raised level of CD34+ cells in DCM patients as compared to normal population [74]. This can be accounted to triggered cytokine cascade due to endothelial dysfunction in DCM [75]. There exists a relationship between increased EPC levels in DCM progression and hence EPCs can be a potential biomarker in DCM.

2) Bispherol A (BPA)

BPA is a widely used chemical mainly in plastic products and when exposed to high temperature, can mix in water and food [76] and thus can be detected in human [77]. Elevated level of BPA has been found in DCM patients as compared to healthy ones [2]. Interesting BPA can give a plausible explanation for the higher incidence of DCM in male. Several Studies showed an existing positive relation between BPA level and SHBG [78] [79]. From the study conducted by Pascual-Fgal et al., it has been demonstrated that the severity of heart failure and hence the risk of cardiac death is associated with the level of SHBG [80]. This can somehow explains the higher incidence of DCM in male population (Table 1).

Table 1. Classification of DCM biomarkers based on pathogenesis.

<table>
<thead>
<tr>
<th>1) Biomarkers of Inflammation</th>
<th>5) Biomarkers of Oxidative Stress</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (C-Reactive Protein) and hs-CRP</td>
<td>Myeloperoxidase</td>
</tr>
<tr>
<td>Neutrophil/Lymphocyte ratio (NLR)</td>
<td>Oxidative low-density lipoproteins</td>
</tr>
<tr>
<td>Chemerin</td>
<td>Urinary &amp; plasma isoprostane</td>
</tr>
<tr>
<td>Galectin-3</td>
<td></td>
</tr>
<tr>
<td>TNF</td>
<td></td>
</tr>
<tr>
<td>Pas (APO-1)</td>
<td></td>
</tr>
<tr>
<td>IL 1, 6, 18</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2) Biomarkers of Myocyte Stress/Stretch</th>
<th>6) Neurohormones</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNP &amp; NT-proBNP</td>
<td>Norepinephrine</td>
</tr>
<tr>
<td>ST2/IL-33</td>
<td>Renin</td>
</tr>
<tr>
<td>ANP</td>
<td>Aldosterone</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3) Biomarkers of Myocyte Injury</th>
<th>7) Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac Troponin I &amp; T</td>
<td>Epithelial Progenitor Cells-EPC</td>
</tr>
<tr>
<td>H-FABP</td>
<td>Bispherol A</td>
</tr>
<tr>
<td>MyBP-C</td>
<td>NGAL</td>
</tr>
<tr>
<td>CK MB Fraction</td>
<td>Beta-Trace Protein (BTP)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4) Biomarkers of Extracellular-matrix remodelling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matrix metalloproteinases</td>
</tr>
<tr>
<td>Tissue Inhibitors of Metalloproteinases</td>
</tr>
<tr>
<td>Collagen Peptides</td>
</tr>
<tr>
<td>Cardiotrophin-1</td>
</tr>
</tbody>
</table>
9. Importance of Studying & Classifying Biomarkers in DCM

Till now there is not a proposed guideline for the treatment and management of DCM. DCM leading to heart failure appears to have a distinct molecular pattern underlying the pathophysiology. The identification of biomarkers for dilated cardiomyopathy presents a distinct challenge due to the diverse potential etiologies. Different etiologies of DCM underline different pathological pathways that will ultimately generate different biomarkers. In this way, it would be wise to be able to classify the different biomarkers involved in DCM based on their pathogenesis. In this review, we manage to classify the newest biomarkers that could be clinically useful. Biomarkers have properties that can give us more information about the disease and may have diagnostic values or prognostic values. By classifying biomarkers involved in DCM in term of pathogenesis and their informative value, this will give us a better insight to understand the underlying etiologies involved and stage of the disease.

10. How to Make These Biomarkers Clinically Useful

We should highlight one of the greatest problems that arises with those biomarkers is the fact that they are not specific to DCM. Many other inflammatory conditions can cause inflammatory biomarkers to be elevated, as it is the same for other type of biomarkers. Therefore, one possible way to make these biomarkers clinically useful in DCM is to make use of a DCM-related “biomarkers modelling score system”. As discussed above, those biomarkers can give us deeper insight about DCM in term of diagnosis, prognosis, risk stratification and effective treatment monitoring. So it would be interesting to be able to further classify those biomarkers in term of biomarkers of diagnosis prognosis, risk stratification or staging of DCM. Research need to be done with such application of biomarkers scoring system model for staging of DCM.

11. Conclusion

DCM remains a complex cardiac disease which requires more understanding. Different aetiologies account for different pathological mechanisms that can lead to the onset of DCM. Different mechanisms mean different pathways which ultimately yield different biomarkers. Many biomarkers have been found to be associated with DMC and these new emerging potential biomarkers, by studying them, can be of great clinical use. Those biomarkers are however not specific to DCM and we yet have to find a proper way to make them clinically useful. One plausible way is to make use a DCM-related biomarkers modelling score system. Research with use of such score system in DCM is yet to be explored and clinically applied.

References

gies in Patients with Idiopathic Dilated Cardiomyopathy: Changing Mortality over the Last 30 Years. European Journal of Heart Failure, 16, 317-324. https://doi.org/10.1002/ejhf.16


with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Korean Circulation Journal, 43*, 93-99. [https://doi.org/10.4076/kcj.2013.43.2.93](https://doi.org/10.4076/kcj.2013.43.2.93)


[38] Sharma, U.C., Pokharel, S., van Brakel, T.J., *et al.* (2004) Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction. *Circulation, 110*, 3121-3128. [https://doi.org/10.1161/01.CIR.0000147181.65298.4D](https://doi.org/10.1161/01.CIR.0000147181.65298.4D)


Abbreviations

DCM: Dilated Cardiomyopathy
LEVF: Left Ventricular Ejection Fraction
VEGF-A: vascular endothelial growth factor A
SDF-1: Stromal Cell-Derived Factor
SHBG: Sex Hormone Binding Globulin